Nascent Pharma Holdings, Inc.
NASC
$0.02
$0.00-8.33%
OTC PK
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -94.38% | -26.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -94.38% | -26.23% | |||
| Cost of Revenue | -37.52% | -44.23% | |||
| Gross Profit | -1.86% | 52.29% | |||
| SG&A Expenses | 107.22% | -26.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 54.85% | -33.98% | |||
| Operating Income | -80.79% | 35.17% | |||
| Income Before Tax | -60.83% | 67.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -60.83% | 67.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.83% | 67.07% | |||
| EBIT | -80.79% | 35.17% | |||
| EBITDA | -84.22% | 26.86% | |||
| EPS Basic | -34.50% | 77.52% | |||
| Normalized Basic EPS | -34.48% | 52.56% | |||
| EPS Diluted | -24.75% | 75.76% | |||
| Normalized Diluted EPS | -34.48% | 52.56% | |||
| Average Basic Shares Outstanding | 19.78% | 46.32% | |||
| Average Diluted Shares Outstanding | 19.78% | 46.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||